Advertisement

CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


FDA Grants RMAT, Fast Track Designations to CB-010 in Relapsed/Refractory Non-Hodgkin Lymphoma

November 29th 2022

The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies

November 28th 2022

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Dr. Janakiram on Future Targets and Strategies for CAR T-cell Therapy in Myeloma

November 22nd 2022

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCL

November 17th 2022

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

CAR Therapy Era Moves Forward With Much Excitement, Lingering Questions

November 16th 2022

CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017.

CAR T-cell Coadministration Strengthens Responses in Childhood B-cell ALL

November 15th 2022

The coadministration of CD19 and CD22 CAR T-cell therapy elicited promising responses and event-free survival rates in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to findings from a phase 2 trial.

CTX130 Allogeneic CAR T-cell Therapy Shows Tolerability, Intriguing Activity in Advanced RCC

November 11th 2022

CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma

November 8th 2022

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

November 4th 2022

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

November 3rd 2022

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Cleveland Clinic Experts Assess Strategies to Accelerate CAR T-Cell Production

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Dr. Hill and Dr. Sauter Discuss the Future of CAR T-Cell Products Agents in Lymphoma

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Cleveland Clinic Experts Discuss the Potential for Allogeneic CAR T-Cell Agents

November 2nd 2022

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Dr. Hill and Dr. Sauter Address Financial Toxicity in CAR T-Cell Therapy

November 2nd 2022

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Dr. Romancik on the Phase 2 PILOT Study of Liso-Cel in Aggressive B-Cell NHL

November 1st 2022

Jason Romancik, MD, discusses the design and key results from the phase 2 PILOT study.

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

October 28th 2022

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

European Commission Approves Second-line Axi-cel for DLBCL/HGBL

October 18th 2022

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

CAR T-cell Therapy CYAD-101 No Longer Under Development for Metastatic CRC

October 14th 2022

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Advertisement
Advertisement